^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Thymic Carcinoma |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Sunitinib is recommended for patients with c-Kit mutations; however these mutations are rare in Thymic carcinomas…
